Autosomal recessive polycystic kidney disease (ARPKD) and Meckel syndrome (MKS) are examples of simple and complex recessive forms of PKD, respectively. ARPKD is considered a monogenic disease, due to PKHD1 mutations, while 16 genes, most commonly TMEM67, cause MKS. They are representatives of a larger group of diseases that result in PKD due to defects in the functioning of primary cilia, ciliopathies. During the previous funding period, increasingly complex mutation screening protocols from Sanger sequencing, through ciliopathy gene panels, to whole exome sequencing (WES) were employed to analyze patients. Further genetic and allelic heterogeneity was found for both diseases, along with evidence of oligogenic inheritance. Mutation screening will continue here employing WES and sophisticated in silico, including 3D modeling approaches, to score variants of uncertain significance (VUS) (Aim 1). Preliminary explorations were made by cellular assays to measure surface localization and protein maturation of the TMEM67 membrane protein, meckelin, with some mutations found to cause folding defects, which were rescued in an enhanced protein-folding environment, lower temperature. Here, cellular assays will be employed for meckelin and the Pkhd1 protein, fibrocystin (FPC), to assess the pathogenicity, penetrance and rescue ability of VUS (Aim 2). The value of potential chemical chaperones to rescue the maturation/localization of folding mutants will be tested employing the cellular systems. Mouse models mimicking the adult ciliopathy phenotypes associated with TMEM67 mutations, such as Joubert syndrome (JBTS), will be generated by engineering two homozygous, hypomorphic, folding mutations employing the CRISPR/Cas9 gene editing method (Aim 3). The adult phenotype will be characterized and chaperone treatment tested. Another discovery during the previous funding period was the greatly enhanced renal phenotype when a Pkhd1 null model (Pkhd1LSL/LSL) and the autosomal dominant PKD (ADPKD) gene, Pkd1, hypomorphic model, Pkd1RC/RC were interbred. While both models alone had a mild renal cystic phenotype, the digenic animals had explosive PKD and early lethality. Here, the pathogenesis associated with the loss of Pkhd1 to make the digenic model will be analyzed by RNA seq and cilia analysis (Aim 4). Since functional Pkhd1 can be reactivated, as a tagged gene/protein (Pkhd1PK) from the Pkhd1LSL model, we will determine if somatic reactivation of Pkhd1 alters the course of the PKD (Aim 4). Using a global expressing Cre, Pkhd1 will be activated at P3 and P14 and the resulting phenotype and expression profile analyzed. This is an important preliminary experiment to determine the phenotypic value of somatic repair of Pkhd1 in this disorder. Overall this study will contribute major insight into the etiology and pathogenicity of recessive forms of PKD, and provide clues for therapeutics.

Public Health Relevance

This study of recessive forms of polycystic kidney disease is designed to better understand causes both in terms of the gene involved and the specific mutation. Mutations that result in protein folding and localization defects will be tested for the ability to be rescue by drug treatment. Also, with an eye to future treatment options, the value of genetically reactivating the disease gene in the cystic kidney will be evaluated.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK059597-20
Application #
10076811
Study Section
Kidney Molecular Biology and Genitourinary Organ Development (KMBD)
Program Officer
Mendley, Susan Ruth
Project Start
2002-04-15
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
20
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Boczek, Nicole J; Hopp, Katharina; Benoit, Lacey et al. (2018) Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants. Eur J Hum Genet 26:1797-1809
Lanktree, Matthew B; Haghighi, Amirreza; Guiard, Elsa et al. (2018) Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing. J Am Soc Nephrol 29:2593-2600
Yin, Meng; Glaser, Kevin J; Manduca, Armando et al. (2017) Distinguishing between Hepatic Inflammation and Fibrosis with MR Elastography. Radiology 284:694-705
Holditch, Sara J; Schreiber, Claire A; Harris, Peter C et al. (2017) B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease. Kidney Int 92:657-668
Schueler, Markus; Braun, Daniela A; Chandrasekar, Gayathri et al. (2015) DCDC2 mutations cause a renal-hepatic ciliopathy by disrupting Wnt signaling. Am J Hum Genet 96:81-92
Sussman, Caroline R; Ward, Christopher J; Leightner, Amanda C et al. (2014) Phosphodiesterase 1A modulates cystogenesis in zebrafish. J Am Soc Nephrol 25:2222-30
Freedman, Benjamin S; Lam, Albert Q; Sundsbak, Jamie L et al. (2013) Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations. J Am Soc Nephrol 24:1571-86
Hoff, Sylvia; Halbritter, Jan; Epting, Daniel et al. (2013) ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3. Nat Genet 45:951-6
Wei, Qing; Xu, Qingwen; Zhang, Yuxia et al. (2013) Transition fibre protein FBF1 is required for the ciliary entry of assembled intraflagellar transport complexes. Nat Commun 4:2750
Leightner, Amanda C; Hommerding, Cynthia J; Peng, Ying et al. (2013) The Meckel syndrome protein meckelin (TMEM67) is a key regulator of cilia function but is not required for tissue planar polarity. Hum Mol Genet 22:2024-40

Showing the most recent 10 out of 24 publications